Chondrosarcomas represent the second most frequent class of primary skeletal malignancies. This tumor type is highly resistant to radiation therapy and currently available chemotherapies, thereby limiting treatment choice to surgical resection. Identifying the mechanisms responsible for chondrosarcoma cell proliferation is therefore crucial for the development of new treatment strategies. Here, we demonstrate a significant reduction in rat chondrosarcoma cell proliferation following treatment with pharmacological inhibitors (SB202190 and PD169316) of p38 mitogen-activated protein (MAP) kinases. In an attempt to dissect possible mechanisms, we investigated the effect of p38 inhibition on promoter activity of cell-cycle genes. Surprisingly, p38 inhibition resulted in upregulation of the activities of all three D-type cyclin promoters. In addition, p38 inhibitors induced increased transcription of the cell-cycle inhibitor p21 waf1/cip1 . As expected, promoter activity of the cyclin A gene, which lies downstream of D-type cyclins and p21 in cell-cycle progression, was strongly reduced by p38 inhibitors. These effects were independent of a cyclic AMP response element and conferred by the proximal 150 nucleotides of the cyclin A promoter. Decreased transcription was accompanied by greatly reduced cyclin A protein levels upon p38 inhibition. These observations indicate complex regulation of chondrosarcoma cell-cycle progression by p38 signaling, and suggest that components of p38 MAP kinase pathways may be effective targets in the treatment of these tumors.
Chondrosarcomas represent the second most frequent class of primary skeletal malignancies. This tumor type is highly resistant to radiation therapy and currently available chemotherapies, thereby limiting treatment choice to surgical resection. Identifying the mechanisms responsible for chondrosarcoma cell proliferation is therefore crucial for the development of new treatment strategies. Here, we demonstrate a significant reduction in rat chondrosarcoma cell proliferation following treatment with pharmacological inhibitors (SB202190 and PD169316) of p38 mitogen-activated protein (MAP) kinases. In an attempt to dissect possible mechanisms, we investigated the effect of p38 inhibition on promoter activity of cell-cycle genes. Surprisingly, p38 inhibition resulted in upregulation of the activities of all three D-type cyclin promoters. In addition, p38 inhibitors induced increased transcription of the cell-cycle inhibitor p21 waf1/cip1 . As expected, promoter activity of the cyclin A gene, which lies downstream of D-type cyclins and p21 in cell-cycle progression, was strongly reduced by p38 inhibitors. These effects were independent of a cyclic AMP response element and conferred by the proximal 150 nucleotides of the cyclin A promoter. Decreased transcription was accompanied by greatly reduced cyclin A protein levels upon p38 inhibition. These observations indicate complex regulation of chondrosarcoma cell-cycle progression by p38 signaling, and suggest that components of p38 MAP kinase pathways may be effective targets in the treatment of these tumors. Oncogene (2004) Chondrosarcomas represent the second most common skeletal neoplasia (Aigner, 2002) . This tumor type is propagated by neoplastic chondrocytes involved in producing the abundant cartilaginous tumor matrix (Pring et al., 2001; Aigner, 2002; Mollano et al., 2002) .
Therapeutic interventions are limited to surgical resection of the tumor and a large region of the marginal healthy tissue, since radiation or chemotherapy is generally not effective. This is, in part, due to limitations in the current knowledge of the oncogenic mechanisms involved in the transformation of chondrocytes and the biology of these tumors. New insights into the mechanisms regulating proliferation of neoplastic chondrocytes may therefore contribute to the development of novel therapeutic interventions over-riding their resistance to chemotherapy treatments.
Neoplasias commonly result from defects in the regulatory pathways controlling cell-cycle progression (Weinberg, 1995; Carnero, 2002) . The majority of neoplastic transformations involve alterations in the mechanisms regulating cyclin-dependent kinase (CDK) activity. There are at least three different mechanisms responsible for uncontrolled cellular proliferation: (1) untimely upregulation of cyclin expression, the regulatory subunits of CDKs, (2) increased activity of CDK-activating kinases (CAKs) and/or phosphatase cdc25, and (3) inactivation of CDK inhibitors (CKIs). For example, while overexpression of cyclin D1 and cyclin A has been implicated in the pathogenesis of various cancers, such as breast cancer and hepatocellular carcinoma, activating mutations in the Cdc25 gene are involved in the development of head and neck cancer (Carnero, 2002) . Also, inactivating mutations in CKIs are common characteristics of leukemia, lymphomas, and breast cancer (Carnero, 2002) . Therefore, it is likely that most neoplasias, including chondrosarcomas, show altered regulation of cell-cycle genes.
Emerging evidence points to roles of p38 mitogenactivated protein (MAP) kinases in cell-cycle control (Ambrosino and Nebreda, 2001) , and demonstrates the functions of p38 in different aspects of oncogenesis, such as proliferation and metastasis in various tissues (Greenberg et al., 2002; Kakonen et al., 2002; Neve et al., 2002; Royuela et al., 2002; Shemirani and Crowe, 2002) . These effects are likely mediated, at least in part, by direct and/or indirect regulation of cell-cycle genes. For example, p38 was shown to promote melanoma and breast cancer cell proliferation through ATF-2-mediated upregulation of cyclin D1 (Recio and Merlino, 2002) . However, p38 involvement in cell-cycle regulation is likely more complex and still not well explored. For example, there is evidence for a role of p38 in the regulation of cyclin D1 protein ubiquitination and subsequent degradation through direct phosphorylation of a threonine residue (Casanovas et al., 2000) . Furthermore, both positive (Crawley et al., 1997; Maher, 1999; Juretic et al., 2001; Recio and Merlino, 2002; Zhao et al., 2002) and negative (Diehl et al., 2000; Puri et al., 2000; Alderton et al., 2001; Smalley and Eisen, 2002) roles of p38 in cell proliferation have been described, suggesting that the mitogenic and antimitogenic functions of p38 are dependent on the cell type and possibly other factors.
We have previously demonstrated roles of the transcription factors ATF-2 and CREB, two potential targets of p38, in the regulation of the cyclin D1 and cyclin A promoters in chondrocytes (Beier et al., 1999a (Beier et al., , 2000 (Beier et al., , 2001 Beier and LuValle, 2002) . We therefore asked whether p38 signaling is involved in the regulation of chondrosarcoma cell proliferation. We investigated the effect of p38 inhibition on rat chondrosarcoma (RCS) cell proliferation through the use of two specific pharmacological inhibitors (PD169316 and SB202190), and an inactive analogue (SB202474). We examined the effects of p38 inhibitors on multiplication of exponen- (Mukhopadhyay et al., 1995) were plated in six-well plates at an initial density of 1 Â 10 4 cells/cm 2 , and incubated in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin (50 U/ml), and streptomycin (50 mg/ml) at 371C, under 5% CO 2 . After 8 h, cells were untreated (control) or treated with DMSO (vehicle), 10 mM SB202474 (inactive control), PD169316, or SB202190 (all from Calbiochem) for 48 h. Cells were then trypsinized and counted using a hemocytometer. The results represent average and standard deviations from three independent experiments (each performed in duplicate) as a percentage of the values of untreated cells. (b) Quantification of the effect of p38 inhibition on RCS cell number using MTT assay. In all, 5 Â 10 3 cells were plated into each well of a 96-well tissue culture dish for 8 h. Cells were then left untreated (control) or treated with DMSO, 10 mM SB202474, PD169316, or SB202190, for 36-48 h. A measure of 20 ml of MTT reagent (Roche) was then added to each well. After 4 h, each well received 100 ml solubilization buffer and incubated overnight at 371C, under 5% CO 2 . Absorbance was then determined at a wavelength of 600 nm (reference 600 nm). The results represent average and standard deviations from three independent experiments (each performed in quadruplicate). (c) p38 MAP kinase inhibition has no effect on RCS viability. RCS cells were seeded in six-well plates at a density of 1 Â 10 4 cells/cm 2 and allowed 8 h for recovery. Cells were then treated with 10 mM SB202474, PD169316, or SB202190 for 24 h (371C, 5% CO 2 ). Subsequently, cells received 1 mg/ml propidium iodide and Hoechst 33358 stain and were left to incubate for 30 min (371C, 5% CO 2 ) before microscopic inspection. All images were taken by fluorescence microscopy with a Zeiss Axiovert S1000 microscope. (d) p38 inhibitors reduce CHOP activity. RCS cells were plated in 24-well plates at a concentration of 1.5 Â 10 4 cells/ml and transfected with 2 mg pFR-Luc (Stratagene), 0.5 mg pFA-CHOP (Stratagene), and 0.02 mg pRlCMV (Promega) for standardization, using Fugene6 (Roche). After 6 h, cells were treated with 10 mM SB202474, PD169316, or SB202190 for 48 h (371C, 5% CO 2 ). Cells were then harvested, and firefly luciferase activity was measured and standardized to Renilla luciferase activity as described (Beier et al., 1999a) . All the results represent average and standard deviations of three independent experiments (performed in triplicate each). Treatment with PD169316 or SB202190 resulted in reduced CHOP activity, confirming inhibition of p38 by these compounds p38 in chondrosarcoma proliferation D Halawani et al tially growing RCS cells using hemocytometer cell counts and MTT assays (Figure 1a, b) . p38 inhibition with either compound resulted in a significant reduction in cell number in both assays. A small reduction in cell number (compared to DMSO controls) was also observed using the control SB202474, indicating that this compound has biological activities. However, effects of the inhibitors were much larger, indicating that specific inhibition of p38 signaling results in a reduction in RCS cell numbers.
To eliminate the possibility of treatment-induced cell death, we examined RCS cell viability and mortality with Hoechst dye (33258) and propidium iodide staining, respectively (Figure 1c) . Treatment with PD169316 and SB202190 did not affect the number of cells stained with propidium iodide compared to SB202474, suggesting that these inhibitors do not induce RCS cell death. However, phase-contrast and Hoechst stain images showed an overall decrease in the density of cells treated with p38 inhibitors, particularly with SB202190.
To confirm that the pharmacological inhibitors affect p38 signaling in RCS cells, we employed a commercial assay based on transcriptional activation by CHOP, a well-documented substrate of p38 (Wang and Ron, 1996; Zhu and Lobie, 2000) . Both PD169316 and SB202190 caused a greater than 50% reduction in CHOP activity, confirming p38 inhibition by these compounds in our system (Figure 1d ). Therefore, our results suggest that p38 inhibition does reduce RCS cell numbers through reduced proliferation with no effects on cell death. It is important to point out that studies in our lab have shown that p38 inhibitors do not affect proliferation of primary nontransformed chondrocytes (Stanton et al., unpublished observation), indicating that the effects of p38 on cell proliferation are specific for transformed chondrogenic cells. Similar results have been obtained in a recent study (Yosimichi et al., 2001 ) where p38 inhibition results in a reduced mitogenic response to connective tissue growth factor in a human chondrosarcoma cell line, but not in primary chondrocytes.
We attempted to dissect a possible mechanism(s) through investigating the effects of p38 inhibition on the induction of several genes important in cell-cycle progression. D-type cyclins are rate limiting for progression through the G1 phase, and their constitutive overexpression has been shown to increase the proliferative capacity of several cell lines through shortening the G1 phase (Peters, 1994) . Therefore, we first examined the effect of p38 inhibition on the induction of cyclin D1, D2, and D3 promoters. Contrary to our expectations, our results showed strong induction of all D-type cyclin promoters upon p38 inhibition (Figure 2a ). These data suggest that p38 signaling suppresses D-type cyclin expression in chondrosarcoma cells, which appears contradictory to the demonstrated requirement for p38 signaling in RCS proliferation. However, there is evidence that overexpression of D-type cyclins in human fibroblasts can halt cell-cycle progression through the formation of inactive complexes with cdk2 (Dulic et al., 1993) , suggesting that D-type cyclins can suppress cell proliferation. In addition, functions of all three D-type cyclins in growth arrest and terminal differentiation have been described (Kiess et al., 1995; Yan and Ziff, 1995; Meyyappan et al., 1998) . Therefore, it is plausible that induction of one or more of the D-type cyclin genes by p38 inhibitors could contribute to decreased proliferation of RCS cells. Alternatively, cyclin D repression by p38 signaling could be counteracted by effects on other positive or negative regulators of cell-cycle progression.
Therefore, we next addressed the question of whether the observed reduction in RCS proliferation by p38 inhibition correlates with increased expression of the CDK inhibitor p21
, which is expressed in chondrocytes (Beier et al., 1999b) . Our results indicate that p21 waf1/cip1 promoter activity is strongly induced upon p38 inhibition (Figure 3) . Consistently, the increase in Figure 2 p38 inhibition leads to upregulation of D-type cyclin promoter activities. RCS cells were plated in 24-well plates at a concentration of 1.5 Â 10 4 cells/ml and transfected with 3 mg of À1745CD1Luc (Albanese et al., 1995) , CD2-1624, or CD3-3300 (Brooks et al., 1996) (encoding fragments of the cyclin D1, D2, and D3 promoters, respectively, upstream of the firefly luciferase gene), and 0.02 mg pRlCMV (Promega, using Fugene6 (Roche). After 6 h, cells were treated with DMSO or 10 mM SB202474, PD169316, or SB202190 for 48 h (371C, 5% CO 2 ). Cells were then harvested, and firefly luciferase activity was measured and standardized to Renilla luciferase activity as described (Beier et al., 1999a) . All the results represent average and standard deviations of three independent experiments (performed in triplicate each). p38 inhibition results in increased activity of all three D-type cyclin promoters Figure 3 p38 inhibition causes increased p21 gene transcription. RCS cells were transfected with pGl p21 H2320 (Beier et al., 1999b) , containing a 2320-nucleotide fragment of the human p21 promoter, and pRLCMV. Transfections and analyses were performed as indicated in Figure 2 . p38 inhibition results in increased transcription from the p21 promoter promoter activity was equivalent to that observed for D-type cyclin promoters for both PD169316 and SB202190. This raises the possibility that inhibitor effects on D-type cyclin and p21 promoters may counteract each other, possibly resulting in little net effect on CDK activity. However, since numerous posttranscriptional regulatory steps (e.g. changes in cyclin or CKI mRNA and protein stability, CDK phosphorylation status, etc.) control CDK activity, our results did not allow conclusions about the effects of p38 inhibitors on CDK activity. Thus, it was necessary to examine the effect of p38 inhibition on targets downstream of D-type cyclins and CKIs.
Cyclin A expression is necessary for passage through the S phase of the cell cycle. Cyclin A gene transcription Figure 4 p38 inhibition results in reduced activity of the cyclin A promoter. (a) Cyclin A promoter vectors used: p707CycALuc, containing a 707-nucleotide fragment of cyclin A promoter, p707mutCycALuc with a mutant CRE sequence, and p157CycALuc, containing a 157-nucleotide fragment of the cyclin A promoter (Nakamura et al., 1995; Shimizu et al., 1998) . (b) p38 inhibition strongly reduces cyclin A promoter activity. RCS cells were transfected with p707CycALuc and pRLCMV. Transfections and analyses were performed as indicated in Figure 2 . p38 inhibition results in markedly reduced activity of the cyclin A promoter. (c) p707CycALuc, p707mutCycALuc, and p157CycALuc were transfected into RCS cells, together with pRLCMV. At 48 h after transfection, cells were harvested and analysed as described in Figure 2 . Mutation of the CRE or deletion of the upstream 550 nucleotides results in decreased activity of the cyclin A promoter. (d) p707mutCycALuc and p157CycALuc were transfected into RCS cells together with pRLCMV. Treatment with p38 inhibitors and analyses of transfection results were performed as described in Figure 2 . Activity is shown as percentage of the activity of each promoter in the presence of DMSO. Activities of both promoters were reduced to a similar degree as the wild-type promoter by p38 inhibitors. (e) Subconfluent RCS cells were incubated with 10 mM SB202474, PD169316, or SB202190 for 24 h and harvested for protein analyses. In all, 20 mg of protein was separated on SDS gels, blotted, and analysed for cyclin A protein expression (antibody SC751, Santa Cruz). Inhibition of p38 signaling results in reduced amounts of cyclin A protein p38 in chondrosarcoma proliferation D Halawani et al is regulated by E2F transcription factors (Sylvester et al., 1998) , and therefore lies downstream of D-type cyclins and CDK inhibitors. Since it represents an accurate marker of S-phase initiation, we expected to observe a decrease in its transcription with p38 inhibition. We first tested the effects of p38 inhibitors on the wild-type cyclin A promoter (p707CycALuc, Figure 4a ). Consistently, cyclin A promoter activity was strongly attenuated in cells treated with PD169316 and SB202190 compared to the controls (Figure 4b ). This supports our proliferation data, and indicates that p38 inhibition does indeed delay cell-cycle progression in RCS cells.
We have recently demonstrated that the transcription factors ATF-2 and CREB regulate cyclin A transcription in chondrocytes through a cyclicAMP response element (CRE) (Beier et al., 2000; Beier and LuValle, 2002) . Since both ATF-2 and CREB can be activated by p38 signaling, we asked whether the CRE is involved in p38 regulation of the cyclin A promoter. We used three different cyclin A promoter constructs (Nakamura et al., 1995) : wild type (containing 707 nucleotides of the human cyclin A promoter expressing E2F and CRE), a variant of the 707-nucleotide promoter in which the CRE has been mutated, and a shorter promoter construct containing a 157-nucleotide promoter fragment containing E2F-like sequences, but not the CRE (Figure 4a ). As expected, the CRE sequence is necessary for basal cyclin A promoter activity in exponentially growing RCS cells since its mutation or deletion significantly reduces cyclin A transcription (Figure 4c ). However, all three promoter constructs conferred a similar response to p38 inhibition (Figure 4d ), indicating that p38 regulation of cyclin A transcription is independent of the CRE and possibly independent of ATF-2 and CREB. In addition, removal of most of the upstream sequences of the cyclin A promoter did not affect p38 responsiveness, indicating that the cyclin A promoter elements conferring p38 response are located in the proximal 150 nucleotides and possibly include E2F sites (Figure 4d) .
Finally, we examined whether p38 inhibition also affects cyclin A protein expression by Western blotting (Figure 4e ). Incubation with PD169316 or SB202190 results in a marked reduction in cyclin A protein levels, confirming the results from our promoter studies. These data clearly demonstrate that the cyclin A gene is a target gene of p38 signaling in chondrosarcoma cells.
In summary, we have shown that inhibition of p38 signaling results in a drastic reduction in the proliferation of RCS cells, suggesting a potential role for p38 inhibitors (or inhibitors directed at other components of the p38 signaling pathway in chondrosarcoma cells) in the treatment of chondrogenic tumors. These effects are likely mediated by complex effects of p38 signaling on cell-cycle gene expression in RCS cells. Our data suggest that additional cell-cycle genes (such as cdc25A or other CDK inhibitors) are involved in the regulation of cellcycle progression in chondrosarcoma cells. Elucidation of the downstream pathways and target genes of p38 in chondrosarcomas will yield additional insights into the pathogenesis of chondrosarcomas and result in novel strategies for their treatment.
